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Summary
A 51 year old man presented with sepsis in the setting of thioamide-induced agranulocytosis. Empiric broad-spectrum 
antibiotics was followed by directed narrow-spectrum antibiotics, and his neutrophil count recovered with support from 
granulocyte-colony stimulating factor (G-CSF) analogue transfusions. After a brief period of multi-modal therapy for 
nine days including potassium iodide (Lugol’s iodine), cholestyramine, propanolol and lithium to temper his persisting 
hyperthyroidism, a total thyroidectomy was performed while thyroid hormone levels remained at thyrotoxic levels. 
Postoperative recovery was uncomplicated and he was discharged home on thyroxine. There is limited available evidence 
to guide treatment in this unique cohort of patients who require prompt management to avert impending clinical 
deterioration. This case report summarises the successful emergent control of thyrotoxicosis in the setting of thioamide-
induced agranulocytosis complicated by sepsis, and demonstrates the safe use of multi-modal pharmacological therapies 
in preparation for total thyroidectomy.
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Learning points:
 • Thioamide-induced agranulocytosis is an uncommon but potentially life-threatening complication of which all 
prescribers and patients need to be aware.
 • A multi-modal preoperative pharmacological approach can be successful, even when thioamides are contraindicated, 
when needing to prepare a thyrotoxic patient for semi-urgent total thyroidectomy.
 • There is not enough evidence to confidently predict the safe timing when considering total thyroidectomy in this 
patient cohort, and therefore it should be undertaken when attempts have first been made to safely reduce thyroid 
hormone levels.
 • Thyroid storm is frequently cited as a potentially severe complication of thyroid surgery undertaken in thyrotoxic 
patients, although the evidence does not demonstrate this as a common occurrence.
Background
Thioamide-induced agranulocytosis is an uncommon 
but potentially serious complication. In the absence 
of infection, antithyroid medication can normally be 
ceased and other management options considered, such 
as radioactive iodine therapy or total thyroidectomy. 
When the patient also presents with sepsis and remains 
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thyrotoxic, the risks of performing surgery on an 
immunosuppressed patient in this setting are largely 
unknown, but potentially high. Although the safety 
and efficacy of the therapies used in this case have 
been previously reported, there are few data to support 
combined anti-thyroid medication therapy to prepare 
for safe total thyroidectomy. This case highlights the 
potential seriousness of agranulocytosis secondary to 
thioamide therapy, and importantly, it demonstrates the 
safety of performing total thyroidectomy in thyrotoxic 
patients when necessary.
Case presentation
A 51 year old man presented to a regional tertiary hospital 
Emergency Department with palpitations, shortness of 
breath, bilateral lower leg oedema and general malaise. 
His medical history included unexplained macrocytic 
anaemia eight years earlier, and nasopalatine cyst surgery 
in recent weeks. He had a family history significant for 
Hashimoto’s thyroiditis (uncle).
A computed tomography (CT) pulmonary angiogram 
excluded pulmonary embolus and, after he complained 
of abdominal symptoms, a CT abdomen and pelvis 
with contrast excluded abdominal pathology. Thyroid 
studies revealed thyrotoxicosis, with a suppressed 
thyroid-stimulating hormone (TSH) (reference range: 
0.3–4.0 mU/L), a free triiodothyronine (T3) of 30.8 pmol/L 
(reference range: 3.5–6.5 pmol/L) and a free thyroxine 
(T4) of 62.3 pmol/L (reference range: 9.8–18.8 pmol/L) 
(Fig.  1). An electrocardiogram excluded atrial 
fibrillation, demonstrating sinus in origin. A chest xray 
was unremarkable.
He was commenced on carbimazole 10 mg three 
times daily orally and propanolol 40 mg twice daily orally 
(Fig. 1). One month later, he was transferred from a rural 
hospital to the same regional tertiary hospital with a 
temperature of 39.1 degrees celsius and systemic features 
of infection including diaphoresis, nausea and sinus 
tachycardia.
He did not exhibit clinical findings of a goitre, 
orbitopathy, ophthalmopathy, dermopathy, periorbital 
oedema or nail changes consistent with Graves’ disease.
Investigation
Full blood examination revealed a white cell count of 
1.3 × 109/L (reference range: 4.0–11.0/L) and neutrophil 
count of 0.0 × 109/L (reference range: 2.0–8.0/L) (Table 1). 
His C-Reactive Protein (CRP) result peaked at 92.6 mg/L 
(reference range: <2.9 mg/L). He was hyperthyroid, 
with a suppressed TSH, a T3 of 8.0 pmol/L and a T4 
of 21.8 pmol/L (Table  1). A CT sinus demonstrated 
widespread sinusitis, and microscopy and culture of a 
neck ulcer subsequently revealed a Methicillin Sensitive 
Staphylococcus Aureus (MSSA) site infection. Blood 
cultures remained negative.
A diagnosis of Graves’ disease was confirmed with an 
elevated TSH-receptor autoantibody titre of 1.9 U/L at first 
hospital admission, increasing to 3.7 U/L one month later 
on repeat testing (reference range: <1.8 U/L). Although a 
thyroid ultrasound was performed prior to thyroidectomy, 
a thyroid nuclear uptake scan was not performed in 
this case.
Treatment
Carbimazole was ceased immediately (Fig. 1). Piperacillin-
tazobactam 4.5 g three times daily intravenously was 
commenced as empiric therapy for sepsis of unknown 
focus. This was changed to amoxicillin/clavulanic acid 
875 mg/125 mg twice daily orally when the neutrophil 
count was >0.5 × 109/L and culture revealed MSSA, and 
continued for seven days. A G-CSF analogue, filgrastim, 
was commenced at 300 µg daily subcutaneously for three 
days, increased to 480 µg daily subcutaneously for three 
days, and ceased when the neutrophil plus bands count 
reached a total of 1 × 109/L.
The patient developed persistent hypertension and 
an increased pulse rate during his admission, raising 
concerns for emerging thyroid storm. His blood pressure 
peaked at 195/85 and pulse rate at 100 beats per minute 
despite doses of propanolol which commenced at 40 mg 
Table 1 Laboratory investigations on presentation 
demonstrated agranulocytosis one month after 
commencement of carbimazole for a new diagnosis of 
Graves’ disease.
Laboratory test Value Reference range
Full blood examination   
Lymphocyte total 0.9 × 109/L 1.0–4.0 × 109/L
WCC 1.3 × 109/L 4.0–11.0 × 109/L
Neutrophil 0.0 × 109/L 2.0–8.0 × 109/L
Haemoglobin 122 g/L 125–175 g/L
Red Cell Count 4.3 × (10 × 12/L) 4.5–5.9 × (10 × 12/L)
Haematocrit 0.36 L/L 0.41–0.53 L/L
Thyroid function tests 
(1 month post 
starting Carbimazole)
TSH
Free T3
Free T4
<0.005 mU/L
8.0 pmol/L
21.8 pmol/L
0.300–4.000 mU/L
3.5–6.5 pmol/L
9.8–18.8 pmol/L
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twice daily orally, and increased in increments to 80 mg 
four times daily prior to thyroidectomy.
Within five days of ceasing carbimazole, his T3 
levels had increased sharply to 33.4 pmol/L and T4 to 
39.7 pmol/L. He was commenced on lithium 500 mg 
daily orally, cholestyramine 4 g three times daily orally, 
and Lugol’s iodine five to seven drops three times daily 
orally in preparation for total thyroidectomy, which 
was performed by Ear Nose & Throat Surgeons on day 
nine of admission (Fig. 1). A lithium level of 0.2 mmol/L 
(therapeutic range: 0.5–1.0 mmol/L) was performed three 
days after commencement of lithium.
On the day of surgery, thyroid function results had 
improved but were still elevated, with a suppressed TSH, a 
T4 of 31.9 pmol/L and a T3 of 11.8 pmol/L (Fig. 1).
Thyroid gland histology further supported the 
diagnosis of Graves’ disease. The thyroid gland weighed 
50.5 g. Microscopically, there were focal hyperplastic 
changes.
Post surgery, lithium, cholestyramine and Lugol’s 
iodine were ceased. Propanolol was gradually weaned 
over seven days to 40 mg twice daily orally before ceasing. 
Thyroxine 100 µg daily orally was commenced on 
discharge (Fig. 1).
Outcome and follow-up
The patient was discharged home following successful 
total thyroidectomy. There were no complications from 
surgery, specifically with regard to bleeding, recurrent 
Figure 1
Multi-modal anti-thyroid therapy temporises thyrotoxicosis with reduction in thyroid hormone levels prior to semi-urgent total thyroidectomy.
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laryngeal nerve injury or hypoparathyroidism. He has 
remained stable on thyroid hormone replacement 
therapy, with regular thyroid function monitoring with 
his General Practitioner. At follow up nine months post 
surgery he remained euthyroid on replacement thyroxine 
(Fig. 1) with a TSH of 4.0 mU/L and a T4 of 13.1 pmol/L.
Discussion
Agranulocytosis caused by thioamides is uncommon, 
with incidence considered to be around 0.2% and almost 
always developing in the first 90 days of commencement 
of therapy (1, 2). Although the mechanism is not entirely 
known, it is thought that a myelosuppressive effect on 
granulocyte production leads to suppression of neutrophil 
development, possibly due to anti-granulocyte auto-
antibodies and/or direct toxicity at the haematopoietic 
stem cell level (2).
There are a number of pharmacological options 
used historically as monotherapy when thioamides are 
contraindicated in hyperthyroid patients. They each 
have a unique mechanism of action, which are likely to 
be synergistic.
Propanolol is a beta-blocker used to attenuate 
hyperadrenergic symptoms of palpitations, anxiety, heat 
intolerance, shortness of breath and tremor (1). At a 
starting dose of 40–160 mg daily, it has an advantage over 
other beta-blockers in helping decrease the peripheral 
conversion of T4–T3 by being more lipid soluble and 
through inhibition of the 5-monodeiodinase enzyme 
(1). A study published in NEJM in 1978 reported a series 
of 100  patients with thyrotoxicosis who underwent 
successful subtotal thyroidectomy following treatment 
with propanolol as monotherapy, without major 
perioperative or postoperative morbidity and importantly, 
with no cases of thyroid storm (3).
Lithium has a number of beneficial actions in the 
treatment of thyrotoxicosis. Firstly, it inhibits the coupling 
of iodotyrosine residues preventing synthesis of T4 and T3, 
likely through inhibiting the action of TSH on the cyclic 
adenosine monophosphate (cAMP) second messenger 
system (4). Secondly, it inhibits thyroid hormone release 
from the follicular cell (4). Finally, it acts as an adjunct to 
radioactive iodine treatment by promoting its retention 
in the thyroid gland (4).
Lugol’s iodine exerts its effect primarily via the 
autoregulatory Wollf-Chaikoff effect of inhibiting 
iodination of thyroglobulin due to large influx of 
exogenous iodide to suppress new thyroid hormone 
synthesis (1). It has the added benefit of reducing thyroid 
gland vascularity and risk of bleeding in thyroidectomy, 
supporting its role in mitigating the risk of postoperative 
haemorrhage (1, 5).
Cholestyramine is a bile acid sequestrant. Thyroid 
hormones are normally metabolised in the liver where 
they are conjugated with glucuronide and sulphate and 
excreted in the bile. Free thyroid hormones are then 
released in the intestine and are finally reabsorbed. 
Thyrotoxic states are characterised by significantly 
increased enterohepatic circulation of thyroid hormones. 
Cholestyramine reduces these increased hormone levels 
by binding to them and interfering with enterohepatic 
circulation and the recycling of thyroid hormone, 
resulting in enhanced faecal excretion (6).
Corticosteroids reduce the conversion of T4 to T3 
and thyroid hormone release from the follicular cell, and 
although not administered to this patient, have previously 
been recommended for rapid preparation of emergent 
thyroid surgery (7). They are also used to treat and hinder 
the progression of established ophthalmopathy associated 
with Grave’s disease (8).
There are little available data to support combined 
pharmacological therapy regimes for hyperthyroidism 
or for urgent surgical intervention when a patient 
presents profoundly thyrotoxic with the added 
burden of neutropaenic sepsis. The 2016 American 
Thyroid Association guidelines for management of 
hyperthyroidism recommend that patients with Graves’ 
disease be rendered euthyroid with methimazole prior 
to thyroidectomy, and support combined use of beta-
blockade and potassium iodide in the preoperative 
period (9). They also acknowledge that if the need for 
thyroidectomy is urgent or it is not possible to render a 
patient euthyroid, the patient should then be adequately 
treated preoperatively with beta-blockade and potassium 
iodide, and priority made for a surgeon and anaesthetist 
with suitable experience (9).
Radioactive iodine therapy has been used for 
hyperthyroid patients to successfully render them 
euthyroid in the setting of thioamide-induced 
agranulocytosis, and may represent a safe treatment 
alternative for patients with a more stable clinical 
presentation (10). Prior iodine exposure from two recent 
CT scans with intravenous iodine would require a clinically 
unacceptable delay for radioactive iodine therapy in our 
patient, who remained symptomatic in the setting of 
increasing thyroid hormone levels following cessation of 
carbimazole. Secondly, standard practice in Australia is to 
continue thioamide therapy to control hyperthyroidism 
following radioactive iodine administration until the 
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patient is rendered euthyroid. The thioamide-induced 
agranulocytosis in this case represented a contraindication 
for ongoing thioamide therapy.
There are published case reports describing a potential 
role for plasmapheresis to control thyroid hormone levels 
and thyroid storm in the preoperative management of 
patients with thioamide-induced agranulocytosis (11, 
12). However, the most recent American guidelines on 
the use of therapeutic apheresis do not support the use of 
plasmapheresis to manage thyroid hormone excess and 
was therefore not considered in this case (13).
A major concern has always been the potential for 
thyroid storm induced by the trauma of surgery in patients 
who are already hyperthyroid. However, there are many 
case reports of successful and safe total thyroidectomies in 
patients with thyrotoxicosis or with agranulocytosis in the 
setting of thyrotoxicosis (14). A recent retrospective study 
in the United States on 165 patients who underwent total 
thyroidectomy demonstrated that of the 42% of patients 
who were hyperthyroid on the day of surgery, although 
37% developed some form of complication, none of them 
developed thyroid storm (14).
This case presents the unique challenges of managing 
thioamide-induced agranulocytosis complicated by 
thyrotoxicosis and sepsis. The concern for emerging 
thyroid storm during admission added complexity to the 
decision to proceed with early thyroidectomy. There were 
also logistical issues to consider relating to availability of 
a surgeon experienced in thyroidectomy in thyrotoxic 
patients, and availability of an operating theatre.
This case validates the role for multi-modal therapy 
to ameliorate thyrotoxicosis prior to semi-urgent 
total thyroidectomy. Although thioamide-induced 
agranulocytosis in the setting of Graves’ disease is rare, 
there is a risk of rapid deterioration for the patient who 
develops sepsis in this setting.
There remains a grey area when it comes to safe 
timing of surgery in a patient with marked Graves’ 
thyrotoxicosis, and a gap in the knowledge when in comes 
to recommendations on combined pharmacological anti-
thyroid therapy duration in the immediate preparatory 
phase for surgery. This case demonstrates that semi-
urgent thyroidectomy may be safe in the setting of 
thyrotoxicosis. Non-thioamide based therapies may be of 
benefit to temporise the clinical state and may reduce the 
risk of complications.
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